The Canadian health-sciences company is developing the sustained-release Sol-gel program for delivery of medical compounds, including cannabinoids like CBD, to provide relief from pain, inflammation, seizures and neurological disorders.
With the use of an applicator, Sol-gels are taken via the nose and rapidly gel upon contact with mucosal tissue.
PreveCeutical's announcement marks the end of the second testing phase of Sol-gel in which the company successfully developed wholly-water based, CBD-infused formulations that incorporated both acid and neutral cannabis-extract forms.
READ: PreveCeutical Medical wins approval to acquire human tissue for final phase of Sol-gel technology testing
The third and final stage of the Sol-gel program is currently underway. The third phase is expected to assess and profile cannabinoid release from the extract infused Sol-gels, as well as how CBD is deposited into nasal mucosal tissue (ex vivo). The company will also conduct a toxicity evaluation.
"It will be exciting to see how these ongoing ex-vivo studies conducted using human explanted tissues may help us get an early read out on our proprietary drug delivery applicator device for the targeted central nervous system delivery of cannabinoids,’ said Mak Jawadekar, PreveCeutical's president and chief science officer.
CBD Sol-gel formulations
The CBD Sol-gel formulations are expected to allow for the direct and prolonged delivery of cannabinoids to a patients' central nervous system.
Future studies, outside of the current Sol-gel program, may involve pre-clinical/clinical evaluation of the CBD Sol-gel formulations as the company's medicinal cannabis division hopes to offer a broad product range of formulations that can be tailored to specific medical conditions.
PreveCeutical, based in Vancouver, is also advancing non-addictive analgesic peptides as a replacement to the highly addictive analgesics such as morphine, fentanyl and oxycodone, and a therapeutic product for treating athletes who suffer from concussions (mild traumatic brain injury).
The company’s stock was flat at C$.045 in Canada but fell 2.5% to $0.035 on the OTC Markets.
Contact the author: [email protected]
Follow him on Twitter @PatrickMGraham